Molecular diagnostic outfit Insight Genetics has entered into an international licensing agreement with GE Healthcare’s Clarient Diagnostic Services, company officials announced today.

Through the agreement, Clarient will be granted worldwide licensing rights to develop a genetic test for the anaplastic lymphoma kinase (ALK) biomarker.

“Insight and Clarient share a dedication to enhancing personalized cancer care,” said Insight CEO Eric Dahlhauser. “We’re pleased to work with Clarient, a leader in cancer diagnostics with a strong commitment to developing tests that address targeted therapies, toward advancing this common goal.”

The ALK biomarker is useful in diagnosing forms of lung and other cancers. Insight has partnered with various entities throughout its history to develop better diagnostic methods that incorporate the company’s test for ALK mutations.